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OBJECTIVES: To evaluate the safety and long-term efficacy of computed tomography-guided percutaneous
ethanol ablation for benign primary and secondary hyperfunctioning adrenal disorders.
METHOD: We retrospectively evaluated the long-term results of nine patients treated with computed tomography-
guided percutaneous ethanol ablation: eight subjects who presented with primary adrenal disorders, such as
pheochromocytoma, primary macronodular adrenal hyperplasia and aldosterone-producing adenoma, and one
subject with Cushing disease refractory to conventional treatment. Eleven sessions were performed for the nine
patients. The patient data were reviewed for the clinical outcome and procedure-related complications over ten years.
RESULTS: Patients with aldosterone-producing adenoma had clinical improvement: symptoms recurred in one
case 96 months after ethanol ablation, and the other patient was still in remission 110 months later. All patients
with pheochromocytoma had clinical improvement but were eventually submitted to surgery for complete
remission. No significant clinical improvement was seen in patients with hypercortisolism due to primary
macronodular adrenal hyperplasia or Cushing disease. Major complications were seen in five of the eleven
procedures and included cardiovascular instability and myocardial infarction. Minor complications attributed to
sedation were seen in two patients.
CONCLUSION: Computed tomography-guided ethanol ablation does not appear to be suitable for the long-
term treatment of hyperfunctioning adrenal disorders and is not without risks.
KEYWORDS: Ablation Techniques; Adrenocortical Adenoma; Pheochromocytoma; ACTH-independent Macro-
nodular Adrenal Hyperplasia; Cushing Disease.
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’ INTRODUCTION
Laparoscopic adrenalectomy is the standard of care for
hyperfunctioning benign adrenal disorders, such as pheo-
chromocytomas and cortisol- or androgen-producing adeno-
mas. It is also a therapeutic option for aldosterone-producing
adenomas (APAs), adrenal hyperplasia resistant to medi-
cal treatment, and adrenocorticotropic hormone (ACTH)-
dependent hypercortisolism, in which the source of ACTH
production cannot be removed. Although considered safe, it
is associated with an overall mortality of 0.2% and a mean
length of stay of 3.3 days (1). Computed tomography (CT)-
guided percutaneous instillation of sclerosing agents, such as
absolute ethanol or acetic acid, has been used as an
alternative treatment for adrenal lesions because these agents
lead to coagulative necrosis (2–9). Potential advantages over
laparoscopic surgery include lower complication rates,
reduced length of stay and lower costs; however, few reports
have been published to date, and none reported long-term
follow-up data. The objective of this study was to evaluate
the safety and efficacy of CT-guided percutaneous ethanol
ablation (PEA) in a group of patients with hyperfunctioning
benign adrenal disorders with long-term follow-up.
’ MATERIALS AND METHODS
Subjects
After institutional review board approval, we assessed our
institutional clinical database. We retrospectively reviewed data
from nine consecutive patients who underwent adrenalDOI: 10.6061/clinics/2016(10)08
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CT-PEA from March 2004 to July 2005. All patients were
deemed unfit for surgery at that time. Written informed consent
was obtained from all subjects. Seven patients (77.8%) were
female. The mean age was 52.9 years (range, 38-71 years).
Follow-up duration ranged from 1 to 110 months (Table 1).
The diagnoses of the patients were APA (2 cases),
pheochromocytoma (3 cases), primary macronodular adrenal
hyperplasia (PMAH, 3 cases – also known as ACTH-inde-
pendent macronodular hyperplasia), and hypercortisolism
due to Cushing disease refractory to conventional treatment
(transsphenoidal hypophysectomy, pituitary radiotherapy
and ketoconazole, 1 case). One of the patients with pheochro-
mocytoma had an ACTH-producing pheochromocytoma
(subject 6). All of the patients had biochemically proven
adrenal hyperfunction before the procedure (elevated urin-
ary metanephrines, high urinary cortisol levels and no
suppression of serum cortisol after 1 mg dexamethasone
test, or an aldosterone/plasma renin activity ratio 430 with
hypokalemia and aldosterone 415 ng/mL). No adrenal
venous sampling was performed.
Patients with primary aldosteronism and pheochromocy-
toma received spironolactone and oral alpha-1 adrenergic
receptor antagonists, respectively, for at least one month
before the procedure. Clinical improvement after treatment
was evaluated by clinical signs and symptoms, reduction in
the number or dosage of medications, and changes in
laboratory examinations (endocrine markers, hormones and
biochemistry) during the follow-up.
Data regarding one of the subjects (patient 6) have already
been reported (10).
Adrenal lesion characteristics
Patients with APA (2) or pheochromocytoma (3): Each patient
had only one nodule. Mean tumor size was 4.0 cm (range,
2.5-7.0 cm). Histopathological analysis was available from
the 3 patients with a clinical diagnosis of pheochromocy-
toma: in one patient, percutaneous biopsy confirmed
pheochromocytoma (subject 6); in the other two patients,
ultimately performed adrenalectomy showed necrotic neo-
plasm (subject 7) and pheochromocytoma (subject 8).
Patients with PMAH (3): All had bilateral, enlarged
macronodular adrenal glands. Histopathological analysis
was available for two patients; in both cases, the histopatho-
logical results were consistent with the clinical diagnosis of
PMAH: from percutaneous biopsy in subject 1 and from
subsequent adrenalectomy in subject 3.
Table 1 - Patient Data.
Pt Age (y)
and
Gender
Diagnosis Lesion treated Ethanol volume in ml
(ethanol volume per
weight in ml/kg)
Anesthesia Complications Clinical results
1 51 F PMAH Left
macronodular
adrenal gland
40 (0.6) Conscious sedation None Failure
1 51 F PMAH Right and left
macronodular
adrenal glands
R: 20 / L: 30 (0.8) Conscious sedation None Clinical improvement;
recurrence and repeated
PEA 10 months later
1 52 F PMAH Right and left
macronodular
adrenal glands
R: 20 / L: 70 (1.4) General anesthesia None Clinical improvement;
recurrence and
adrenalectomy 68 months
later
2 45 F PMAH Right and left
macronodular
adrenal glands
R: 35 / L: 25 (0.8) Conscious sedation None Failure, lost to follow-up
3 65 F PMAH Left
macronodular
adrenal gland
40 (0.4) Conscious sedation Minor: Transient drowsiness,
bradypnea and hypoxemia
(midazolam)
Failure, adrenalectomy
5 months later
4 38 F Cushing
disease
Right and left
adrenal glands
R: 40 / L: 40 (1.0) Conscious sedation Major: Hypotension, CNS
depression and MI
Failure
5 50 F APA 3.0 cm nodule
in the left
adrenal gland
50 (1.0) Conscious sedation Minor: Agitation, short and
self-limited hypoxia (sedation)
Clinical improvement for
110 months
6 71 M Pheo 4.5 cm nodule
in the left
adrenal gland
40 (0.7) Conscious sedation Major: Hypertension followed
by hypotension
Clinical improvement;
recurrence and
adrenalectomy 83 months
later
7 56 F Pheo 7.0 cm nodule
in the right
adrenal gland
100 (1.4) General anesthesia Major: Hypertension and
tachyarrhythmia, admitted to
ICU
Clinical improvement,
adrenalectomy 1 month
later (synchronous to
colectomy)
8 61 F Pheo 3.0 cm nodule
in the left
adrenal gland
40 (0.6) General anesthesia Major: Hypertension and
tachycardia, admitted to ICU
Clinical improvement;
recurrence and
adrenalectomy 39 months
later
9 39 M APA 2.5 cm nodule
in the left
adrenal gland
40 (0.5) General anesthesia Major: Symptomatic wide-QRS
tachycardia and hypertension;
transient neurological
symptoms
Clinical improvement;
recurrence and
adrenalectomy 96 months
later
Pt = Patient, M = Male, F = Female, PMAH = Primary Macronodular Adrenal Hyperplasia, APA = Aldosterone-producing adenoma,
Pheo = Pheochromocytoma, R = Right; L = Left; CNS = Central nervous system; MI = Myocardial infarction; ICU = Intensive care unit.
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Patient with Cushing disease: Both adrenal glands were
normal on CT.
CT-PEA protocol
All of the procedures were performed by an experienced
interventional radiologist (M.R.M). One of the patients
underwent three PEA sessions; thus, there were a total of
eleven procedures.
Seven of the procedures were performed using local
anesthesia with lidocaine and conscious sedation with intra-
venous meperidine and midazolam, whereas four proce-
dures were performed under general anesthesia.
Patients were placed in the prone position, and a 22-gauge
Chiba needle was inserted into the adrenal target under CT
guidance through a paravertebral access. Absolute ethanol
laced with iodinated contrast medium was then instilled. CT
images were obtained to confirm appropriate distribution of
the ethanol. At the end of the procedure, a non-contrast-
enhanced scan was performed to identify possible complica-
tions. When requested by the referring physician, biopsy was
done at the beginning of the procedure.
All of the patients were treated with only one session,
except for subject 1. The patients with PMAH had PEA
performed in their largest nodules: subject 1 was treated
unilaterally in the first session and bilaterally in the
remaining procedures, subject 2 was treated bilaterally and
subject 3 was treated unilaterally. The patient who had
Cushing disease was treated bilaterally. All of the remaining
patients, who had focal lesions, had PEA performed only in
their single adrenal nodules. Therefore, eleven procedures
were performed in nine patients. The ethanol volume
instilled was calculated based on the nodule volume or
adrenal volume: the mean volume of ethanol injected was
57.3 mL (range, 40.0-100.0 mL) per session or 39.4 mL per
target ablated (range, 20.0-100.0 mL); relative to patient
weight, the mean volume instilled was 0.8 mL/kg (range,
0.4-1.4 mL/kg).
All of the procedures were performed on an inpatient
basis.
ETHICS
Procedures were in accordance with the ethical standards
of the Institutional Review Board and with the Helsinki
Declaration of 1975, revised in 1983.
’ RESULTS
Clinical results
The two patients with APA had clinical improvement
(improvement in hypokalemia and reduction in the dosage
of anti-hypertensive medications). In one patient, PEA
treatment was also associated with normalization of the
aldosterone/plasma renin activity ratio, and she was still in
remission 110 months after PEA. The other patient never had
persistent normalization of the aldosterone/plasma renin
activity ratio and had adrenalectomy for symptoms recur-
rence 96 months after ablation.
All of the patients with pheochromocytoma had improve-
ment of clinical symptoms and laboratory examinations. In
one of them, surgeons decided to perform adrenalectomy
during a colectomy for colon adenocarcinoma one month
after PEA despite clinical improvement after ablation; she
died one year later from metastatic adenocarcinoma. The
other two patients developed clinical recurrence and were
subjected to laparoscopic adrenalectomy 39 and 83 months
later.
One patient with PMAH developed clinical improvement
and normalization of urinary cortisol and fasting glucose
after two sessions of PEA, although ACTH remained
suppressed. She recurred 10 months later and was retreated
with PEA, again with the same results for another 68 months.
She was then subjected to laparoscopic right adrenalectomy,
which required conversion into open surgery and associated
ipsilateral nephrectomy due to intraoperative renal bleeding.
PEA failed in the other two patients with PMAH (one of
them was lost to follow-up 7 months after treatment, and the
other underwent adrenalectomy five months later).
The patient with Cushing disease did not show signs of
improvement after PEA and was kept on medical treatment
(Table 1).
Complications
Complications were classified as minor or major events,
according to the Society of Interventional Radiology’s
guidelines (11).
The review of medical data disclosed only immediate
complications. Of the eleven procedures, five were associated
with major complications, and two were associated with
minor ones (Table 1). No procedure-related deaths were
observed.
Major complications: One patient with APA developed
symptomatic wide-QRS tachycardia and hypertension; this
patient also developed neurologic symptoms approximately
72 hours after the procedure (ataxia, nystagmus and
hemiparesis) and the symptoms resolved after 24 hours
(brain imaging studies performed were normal). The three
patients with pheochromocytoma developed severe intra-
procedural hypertension (up to a mean value of 200 mmHg)
after ethanol instillation that required intensive care for up to
one day; one of the patients also had tachycardia with
bigeminy requiring intravenous nitrates for several hours
after the procedure for pressure control; and another patient
had transitory hypotension afterward that needed vasoactive
drugs. One patient, with Cushing disease, developed severe
hypotension, central nervous system (CNS) depression and
hypoxemia, and acute myocardial infarction, although
coronary angiography performed the following day showed
only left ventricular hypertrophy and normal coronary
arteries.
Minor complications: Psychomotor alterations attributed
to midazolam were seen in two patients, one of whom also
developed short and self-limited hypoxia due to sedation.
’ DISCUSSION
We presented here the long-term results of CT-PEA for the
treatment of hormonally active adrenal lesions.
According to our results, PEA does not appear to be a
reasonable alternative treatment to hormonally active adre-
nal lesions. Overall, the success rate was low (only one out of
nine patients, 11.1%, was cured) and the incidence of
complications was high (seven out of eleven procedures,
63.6%).
Other groups have reported treating functioning adrenal
lesions with percutaneous chemical ablation (Table 2), for a
total of 40 pheochromocytomas (5), 18 APAs (3,6–9) and
12 cortisol-producing adenomas (CPA) (6,7,9). Except for
one patient who did not present a complete response to
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treatment (7) and another who recurred four years after
ablation and was successfully retreated (8), both of them
with APA, all other patients were considered to have been
successfully treated. The only complications reported by
these groups were pain (6,7,9), periprocedural increase in
blood pressure (5,7,9) and adrenal insufficiency in one case
(9). One patient, with a cortisol-producing adenoma, had
severe pain and marked hypertension during the procedure,
prompting its interruption, and had no complications when
retreated during epidural anesthesia (7). No treatment was
performed under general anesthesia by these groups.
Although technical differences, such as the ablating agent
employed (acetic acid or ethanol), volume instilled, size of
lesions, and number of treatment sessions performed, might
play a role in explaining the seemingly better results reported
in the literature, we believe that our longer follow-up data
show that late recurrence may limit treatment in patients
with PEA. Excluding the patient who underwent adrena-
lectomy one month after the ablation and who was clinically
controlled, our patients who improved with PEA needed
surgery 39, 68, 83 and 96 months after ablation, and only one
was still cured after 110 months of follow-up; this pattern of
late recurrence, also described by Chang et al (8), might not
have been more often described due to the other published
follow-ups ranging from 15 to 54 months.
PEA proved to be an even less effective procedure for the
treatment of hypercortisolism secondary to nonfocal adre-
nal diseases, such as Cushing disease or macronodular
hyperplasia. In our limited series, only one of the three
patients with macronodular hyperplasia (subject 1) devel-
oped remission after ablation (lasting 10 and 68 months,
after the second and third treatment sessions, respectively).
The single patient with Cushing disease was also not cured
after undergoing one session of bilateral adrenal PEA.
Whether a greater number of ablation sessions or the use of
acetic acid in these cases could have yielded better results
remains unclear.
We observed significant cardiovascular side effects of PEA
in several of these patients with adrenal disorders. All of the
patients with pheochromocytoma received alpha-1 adrener-
gic receptor antagonists for at least one month before the
procedure, as is typically done before adrenalectomy (12),
although it did not prevent intraprocedural hypertension.
Hypertensive crisis is a known complication of surgical
treatment of this disorder (13). During adrenalectomy for
pheochromocytoma, adrenal vein clamping prevents part of
the catecholamines stored in the tumor from entering the
blood circulation, and they are removed with tumor excision.
Consequently, severe hypertension may occur during tumor
manipulation in surgery but not after its completion; hypo-
tension is the most common hemodynamic complication in
the postoperative period (13). However, in adrenal PEA,
catecholamines may be released during or after treatment,
and hypertension might be observed several hours after the
procedure. Additionally, similar to post adrenalectomy, we
also observed postprocedural hypotension in one of our
patients. Hypertensive crisis during adrenal PEA has not
been previously reported. However, this complication, asso-
ciated with a non-severe ventricular arrhythmia in one case
(14), has been described in patients undergoing radio-
frequency or cryoablation of nonfunctioning adrenal lesions
(14–16) and metastatic pheochromocytomas and paragan-
gliomas (17).
In patients without pheochromocytoma, cardiovascular
effects included hypotension, CNS depression and hypox-
emia, myocardial infarction, and tachyarrhythmia associated
with hypertension. Hypotension and CNS depression and
hypoxemia observed in subject 4 could have resulted from
the systemic effects of ethanol (18), as was also reported
in one subject treated by Minowada et al (19); this may
have been potentiated by prior benzodiazepine and opiate
administration. Hypotension has also been observed in
image-guided PEA for treating other organs, such as
hepatocellular carcinoma in the liver and several cases of
cardiovascular collapse have been reported (20,21). Acute
myocardial infarction followed by an unremarkable coronary
angiography may have been related to an increased
myocardial demand secondary to left myocardial hypertro-
phy and a lower oxygen supply as a result of hypotension
and transitory hypoxemia; transient elevation of pulmonary
artery pressure and myocardial depression may also result
from ethanol spilling into the systemic circulation (22).
Retrospectively, another diagnostic possibility (which has
more recently been reported after adrenal cryoablation (15))
would have been the apical ballooning syndrome: it
corresponds to reversible cardiomyopathy precipitated by
stress that presents with clinical features of myocardial
infarction, with elevation of cardiac enzymes, and temporary
left ventricular dyskinesia without obstructive coronary
disease (23). Cardiac arrhythmias may be related to both
hyperaldosteronism (24) and ethanol (25).
The complications of adrenal PEA herein reported
prompted us to change from doing the procedure under
sedation to under general anesthesia. Patients with pheo-
chromocytoma who undergo PEA, similar to those who
undergo adrenalectomy (13), might need admittance to an
intensive care unit due to hemodynamic instability. General
anesthesia, mechanical ventilation and invasive blood
Table 2 - Published Results on Percutaneous Chemical Ablation of Pheochromocytomas, Aldosterone-Producing and Cortisol-
Producing Adenomas of the Adrenal Gland.
Pheo APA CPA Size: min-max (mean) (cm) Agent Repeated sessions? Follow-up (mo)
Rossi et al. (3) - 1 - 2.0 Ethanol No 17
Liang et al. (9) - 2 1 1.3-3.5 (2.3) Acetic acid No 15-18
Wang et al. (5) 40 - - 1.1-4.1 (NR) Ethanol No 23-54
Minowada et al. (7) - 5 5 1.0-3.8 (2.2) Acetic acida Yes 5-69
Xiao et al. (6) - 9 6 1.9-4.4 (2.8) Ethanol/Acetic acidb Yes 24
Chang et al. (8) - 1 - 1.0 Ethanol Yesc 448c
Our results 3 2 - 2.5-7.0 (4.0) Ethanol No 1-110
Pheo = Pheochromocytomas, APA = Aldosterone-producing adenomas, CPA = Cortisol-producing adenomas, NR = Not reported, Acetic acida = one patient
was submitted to one session of ethanol ablation, Ethanol/Acetic acidb = Ethanol was used for tumors up to 3.0 cm and acetic acid for larger lesions;
Yesc; 448c = patient successfully retreated 4 years after first PEA with another ablation session, but subsequent follow-up time not disclosed.
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pressure monitoring may be important for performing
adrenal PEA safely.
The ideal volume of ethanol administered in PEA is
unclear. Although prior studies of sclerotherapy of vascular
anomalies with ethanol suggest that volumes greater than
1.0 mL/kg are associated with acute morbidity or toxicity
(22), most of our patients were treated with smaller volumes
and still developed complications. The low ethanol volumes
used in Xiao’s study (6) might be safer, although a higher
number of sessions may be required. Wang et al (5) treated
forty benign pheochromocytomas after intraprocedural
phentolamine and reported no hypertensive crisis; the
volume of ethanol instilled in their case was reported to be
‘‘equivalent to size of the tumor’’.
More recently, image-guided radiofrequency ablation
(RFA) has also been successfully used for treating benign
functioning adrenal lesions (26–31). Whereas the ethanol
distribution within tumors is limited by septa and can be
unpredictable, RFA creates a relatively homogeneous abla-
tion zone. It has already been shown to be more effective
than PEA for treating hepatocellular carcinoma (HCC)
(32,33). Analysis of the pooled results from these cohorts
(26–31) is very promising: a total of 55 lesions have been
treated (44 APA, 7 CPA, 3 pheochromocytomas and 1 sex
steroid-producing tumor), with biochemical success in
51 patients and clinical success in 53 of them. Further studies
should compare RFA to laparoscopic adrenalectomy, the
current gold standard for hyperfunctioning adrenal lesions.
Our study has some limitations. It included a small sample
size and heterogeneous population. Its retrospective design
limits the availability of patient data.
In summary, our results indicate that ethanol ablation of
benign adrenal lesions involves significant risks and lacks
long-term efficacy.
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